Skip to main content
SpringerLink
Log in

Introduction: designing nanobiotechnology oversight

  • Special focus: Governance of Nanobiotechnology
  • Published:
Journal of Nanoparticle Research Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Center for Drug Evaluation and Research (CDER) (2010) Manual of policies and procedures: reporting format for nanotechnology-related information in CMC review. CDER, Silver Spring

  • Environmental Protection Agency (EPA) (2008) Toxic substances control act inventory status of carbon nanotubes. Federal Register 73:64946

    Google Scholar 

  • Kuzma J, Romanchek J, Kokotovich A (2008) Upstream oversight assessment for agrifood nanotechnology: a case studies approach. Risk Anal 28:1081–1098

    Article  Google Scholar 

  • National Institute for Occupational Safety and Health (NIOSH) (2009) Approaches to safe nanotechnology: managing the health and safety concerns associated with engineered nanomaterials

  • National Nanotechnology Initiative (NNI) (2010) Supplement to the President’s 2011 Budget. Report prepared by the National Science and Technology Council Committee of Technology, Subcommittee on Nanoscale Science, Engineering, and Technology

  • Paradise J, Tisdale AW, Hall RF, Kokkoli E (2009) Evaluating oversight of human drugs and medical devices: a case Study of the FDA and implications for nanobiotechnology. J Law Med Ethics 37:598–624

    Article  Google Scholar 

  • Ramachandran G, Wolf SM, Paradise J, Kuzma J, Hall R, Kokkoli E, Fatehi L (2010) Recommendations for oversight of nanobiotechnology: dynamic oversight for complex and convergent technologies (cite to publication in this volume)

  • Wolf SM, Ramachandran G, Kuzma J, Paradise J (eds) (2009) Symposium on Developing oversight approaches to nanobiotechnology: the lessons of history. J Law Med Ethics 37:543–789

    Google Scholar 

Download references

Acknowledgments

Preparation of this article was supported by National Science Foundation (NSF) grant #0608791, “NIRT: Evaluating Oversight Models for Active Nanostructures and Nanosystems: Learning from Past Technologies in a Societal Context” (Principal Investigator: S. M. Wolf; Co-PIs: E. Kokkoli, J. Kuzma, J. Paradise, and G. Ramachandran). The views expressed are those of the authors and do not necessarily reflect the views of NSF. Thanks to the project’s Working Group members: Profs. Susan Foote, Ralph Hall, Christy Haynes, Terrance Hurley, Jeffrey Kahn, Bradley Karkkainen, Kristen Nelson, David Pui, T. Andrew Taton, and Elizabeth Wilson (University of Minnesota); Prof. Stephen Ekker (Mayo Clinic College of Medicine); Robert Hoerr (Nanocopoeia, Inc.); Robbin Johnson (Cargill Foundation); George Kimbrell (International Center for Technology Assessment and the Center for Food Safety); Prof. Andrew Maynard (University of Michigan); and Prof. Susanna Hornig Priest (University of Nevada, Las Vegas). Thanks also to the project’s Advisory Board members: David Chittenden (Science Museum of Minnesota); Judy Crane (Minnesota Pollution Control Agency); Prof. Linda Hogle (University of Wisconsin, Madison); Prof. William Kay (Northeastern University); Prof. Milind Kandlikar (University of British Columbia); and Maria Powell (Nanotechnology Citizen Engagement Organization). Thanks to Research Assistant Katie Wolf for editorial assistance with this symposium.

Author information

Authors and Affiliations

  1. Consortium on Law and Values in Health, Environment & the Life Sciences, Law School, University of Minnesota, Minneapolis, MN, 55455, USA

    Leili Fatehi

  2. Consortium on Law and Values in Health, Environment & the Life Sciences, Law School, Medical School, Center for Bioethics, University of Minnesota, Minneapolis, MN, 55455, USA

    Susan M. Wolf

  3. Division of Environmental Health Sciences, School of Public Health, University of Minnesota, Minneapolis, MN, 55455, USA

    Gurumurthy Ramachandran

  4. Humphrey Institute of Public Affairs, University of Minnesota, Minneapolis, MN, 55455, USA

    Jennifer Kuzma

Authors
  1. Leili Fatehi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan M. Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gurumurthy Ramachandran
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jennifer Kuzma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leili Fatehi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fatehi, L., Wolf, S.M., Ramachandran, G. et al. Introduction: designing nanobiotechnology oversight. J Nanopart Res 13, 1341–1343 (2011). https://doi.org/10.1007/s11051-011-0231-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11051-011-0231-4

Keywords

Search

Navigation